Authors' objectives: Background The aim of this health technology assessment (HTA) is to evaluate the safety, effectiveness, cost, cost-effectiveness and budget impact of revascularisation with percutaneous coronary intervention (PCI), coronary artery bypass grafting (CABG) or both (i.e. PCI or CABG) in comparison to optimal medical therapy (OMT) in patients with chronic coronary syndrome (CCS). Ethical, legal, social and organisational issues related to the interventions are also explored.
PROMs; efficacy; effectiveness; safety; costs; economics; cost-effectiveness; budget impact; legal; social; ethical; organisational; Surgical procedures; Pharmaceuticals; Percutaneous coronary intervention (PCI); Coronary artery bypass grafting (CABG); Optimal medical therapy (OMT); chronic coronary syndrome (CCS); major adverse cardiac events (MACE); all-cause mortality; hospitalisation; subsequent revascularisation; health-related quality of life (HRQoL); stent thrombosis; myocardial infarction (MI); stroke; Markov model
10.5
